Phaseline

Targets › TNFSF12

TNFSF12 (Tumor necrosis factor ligand superfamily member 12): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 2; Oncology; next expected readout Oct 2028.

Binds to FN14 and possibly also to TNRFSF12/APO3. Weak inducer of apoptosis in some cell types. (UniProt, O43508)

Open in Phaseline: the race on TNFSF12, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Jiangsu HengRui MedicineAdabelimumab
TWEAK/TNF superfamily ligand antagonist
TNFSF12Phase 2Locally Advanced or Metastatic Non-small Cell Lung CancerOct 2028

Conditions

Locally Advanced or Metastatic Non-small Cell Lung Cancer (1)

Modalities

mixed (1)

Companies

Jiangsu HengRui Medicine (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.